Royalty Pharma plc

Pharmaceutical Preparations·NEW YORK, NY·FY end 12/31·CIK 1802768

CEO Pay Ratio

4:1

Pablo Legorreta

CEO Total Comp

$937.5K

Pablo Legorreta

Median Employee

$349,893

Revenue

$2.4B

FY 2025

Net Income

$770.9M

FY 2025

Free Cash Flow

—

FY 2025

Net Margin

32.4%

Insider Net (180d)

-$38.8M

0 buys / 36 sales

CEO Pay Accountability

CEO comp as % of net income

0.12%

For every $1,000 of profit, $1.22 flows to the CEO.

CEO comp as % of buybacks

0.08%

CEO comp equals 0.8‰ of cash returned to shareholders via buybacks.

5-year history · USD

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	Trend
Revenue	$2.4B	$2.3B	$2.4B	$2.2B	$2.3B
Gross Profit	—	—	—	—	—	—
Operating Income	$1.6B	$1.3B	$1.5B	$307.1M	$1.4B
Net Income	$770.9M	$859.0M	$1.1B	$42.8M	$619.7M
Operating CF	$2.5B	$2.8B	$3.0B	$2.1B	$2.0B
Capex	—	—	—	—	—	—
Free Cash Flow	—	—	—	—	—	—
Buybacks	$1.2B	$229.7M	$304.8M	—	$0
Dividends	—	—	—	—	—	—

Gross Margin	—	—	—	—	—	—
Operating Margin	65.6%	57.1%	63.4%	13.7%	62.5%
Net Margin	32.4%	37.9%	48.2%	1.9%	27.1%
FCF Margin	—	—	—	—	—	—
R&D / Revenue	19.0%	0.1%	2.2%	7.9%	8.7%
Effective Tax	0.0%	0.0%	0.0%	0.0%	0.0%
Debt / Equity	—	—	—	—	—	—
Buybacks / FCF	—	—	—	—	—	—

FY 2025

Executive	Salary	Stock	Options	Bonus / Inc.	Other	Total
Christopher HiteExecutive Vice President & Vice Chairman	$1.3M	—	—	—	—	$1.3M
Marshall UristM.D., Ph.D. Executive Vice President, Research & Investments	$1.3M	—	—	—	—	$1.3M
Terrance CoyneExecutive Vice President & Chief Financial Officer	$1.3M	—	—	—	—	$1.3M
Pablo LegorretaChief Executive Officer	$937.5K	—	—	—	—	$937.5K